Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - HCV
 More »

  • Human iPSC-Derived Hepatocytes
    ... and responsiveness to HCV. (A) Immunostaining shows evidence of markers reported as key for cell attachment (CD81) as well as uptake (Occludin) of HCV. (B) iCell Hepatocytes ...
    5-1-2013
  • Roche, Ascletis to Develop HCV Drug in China
    of hepatitis C virus (HCV). Their mission: to develop a therapy with the potential to provide an effective new treatment option for Chinese patients with HCV. Ascletis will fund ...
    4-15-2013
  • BMS Shores Up R&D after Trial Failure, Plavix Patent Loss
    ... inhibitor daclatasvir to Vertex' investigational nucleotide analogue hep C virus (HCV) polymerase inhibitor VX-135. Earlier last week, BMS confirmed it will shut down the San ...
    4-8-2013
  • BMS, Vertex Plan Phase II Studies of Hep C Combo Therapy
    nucleotide analogue hep C virus (HCV) polymerase inhibitor VX-135. Under a ... treatment-naïve people with genotype 1 HCV infection, planned for the second quarter. ...
    4-5-2013
  • Literature Review: A Flying Drop Becomes a Hanging Drop
    at the various volumes explored. (a) HCV helicase (50 nL). (b) Human serum albumin (50 nL). (c) HCV polymerase (30 nL). (d) HIV RT (15 nL). (e) ITK (30 nL). (f) Lysozyme (15 nL). ...
    4-4-2013
  • Development and Evolution of PCR
    ... Today, most quantitative tests are based on the real-time PCR quantitative analysis with TaqMan probes. PCR-based multiplex tests for HIV, HCV, and HBV are also widely used in most ...
    4-1-2013
  • Receptos Licenses AbbVie Antibody for Co-Development
    ... Immunology is one of five disease areas identified by AbbVie for future activity and growth; the others were HCV, oncology, renal disease, and Alzheimer's disease. Receptos is also ...
    3-13-2013
  • Drug Repurposing Rekindles Promise
    ... In contrast, molecular target-based screening and rational drug design remain the standard for targeting infectious agents (i.e., HIV and HCV) because the pathogen's targets are ...
    1-25-2013
  • BioCryst Halves Staff After Setbacks
    antiviral, and BCX5191 hepatitis C (HCV) programs, for which he said BioCryst will ... of low doses of BCX5191 in chronically HCV-infected chimpanzees, with the goal of ...
    12-7-2012
  • Merger Terminated between Presidio and BioCryst
    and orphan disease indications, including HCV and hereditary angioedema, anchored by ... each other or with other direct-acting antivirals to treat patients with HCV infection. ...
    11-30-2012
  • PerkinElmer Acquires China-Based Diagnostics Company
    of hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV), two clinical quantitative assays that screen for HBV and HCV, and one qualitative assay screen ...
    11-13-2012
  • Vertex Tests Oral HCV Combos with Janssen and GSK
    and with GlaxoSmithKline, to evaluate its HCV drug candidate VX-135, in Phase II studies ... VX-135 is a uridine nucleotide analogue HCV polymerase inhibitor prodrug that acts on ...
    11-1-2012
  • Oncolytic Virus Therapy Firms Merge
    in 42 patients with acute HBV and HCV. Superinfection therapy exploits the phenomenon that infection by one type of hepatitis virus (e.g., HCV) can be abolished following ...
    10-23-2012
  • Dr. Reddy's to Launch $35.7M Public Offer for OctoPlus
    The firm's marketed HCV drug Locteron(tm) is an alfa interferon developed in collaboration ... However, Locteron has been suffering in the market due to the emergence of oral HCV drugs, ...
    10-22-2012
  • BioCryst Buys Presidio in $101M Merger
    chronic hepatitis C virus (HCV) infection. The combined company will have lead programs in infectious and orphan disease indications, including HCV and hereditary angioedema, ...
    10-18-2012
  • More »

    Journal Articles

  • A Bioinformatics Approach to Identify Natural Autoantibodies...
    Nada Vasiljevic, Nevena Veljkovic, Tatjana Kosec, Xue-Zhong Ma, Sanja Glisic, Jelena Prljic, Ana Djordjevic Vujicic, Ljiljana Markovic, Donald R. Branch
    Viral Immunology
    Blood Donors' Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay Viral ... We selected protein hepatitis C virus (HCV) NS5A as a target sequence, motivated by the ...
  • Hepatitis C Videoconferencing: The Impact on Continuing Medical...
    Lorenzo Rossaro, Thu P. Tran, Kanat Ransibrahmanakul, Julie A. Rainwater, Genell Csik, Stacey L. Cole, Colette C. Prosser, Thomas S. Nesbitt
    Telemedicine and e-Health
    care providers' (MDs, NPs/PAs, and RNs) education regarding hepatitis C virus (HCV). ... history, diagnosis, and management of HCV. Improved knowledge was scored from a ...
  • Current Risks of Occupational Blood-Borne Viral Infection
    Arash Mohebati, John Mihran Davis, Donald E. Fry
    Surgical Infections
    B virus (HBV), hepatitis C virus (HCV), and other viruses remain occupational ... Infection with HBV can be prevented by a safe and effective vaccine. Chronic HCV infection ...
  • Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory...
    Monica Notarbartolo, Lydia Giannitrapani, Nicoletta Vivona, Paola Poma, Manuela Labbozzetta, Ada Maria Florena, Rossana Porcasi, Vito Michele Rosario Muggeo, Luigi Sandonato, Melchiorre Cervello, Giuseppe Montalto, Natale D'Alessandro
    OMICS: A Journal of Integrative Biology
    in HCC. We evaluated by RT-PCR the mRNA levels of YY1, YY1AP, RKIP and survivin in 35 clinical HCCs (91% HCV-related), in their adjacent cirrhotic tissues and in 6 healthy livers. ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll